DARE
Dare Bioscience, Inc.Company Information
- Company Name
- Dare Bioscience, Inc.
- CIK
- CIK0001401914
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- DARE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DARE
SEC filing data through
Insider Sentiment
- Last purchase
- 2019-04-11
- Last sale
- —
- Shares purchased (TTM)
- 594,545
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,250,255
- Shares outstanding
- 14,889,832
- Ownership
- 8.40%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -47.37%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 19 | 25 | 23 | 5 | 10 | 16 | 11 | 16 | 4 | 10 | 14 | ||||||
| Other Receivables Net Current | - | - | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Prepaid Expense Current And Noncurrent | 3 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 1 | - | 0 | - | - | - | - | - | 0 | - | 1 | ||||||
| Prepaid Expense Current | 1 | 1 | 2 | 2 | 1 | 1 | 3 | 3 | 4 | 5 | 6 | 7 | ||||||
| Assets Current | 17 | 22 | 27 | 25 | 7 | 12 | 18 | 15 | 21 | 10 | 18 | 22 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | - | ||||||
| Finance Lease Right Of Use Asset | 1 | 1 | 2 | 2 | 3 | 3 | 0 | - | - | - | - | - | ||||||
| Deposits Assets Noncurrent | - | - | - | - | - | - | 0 | 1 | 0 | 1 | 1 | 2 | ||||||
| Other Assets Noncurrent | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 22 | 28 | 32 | 31 | 13 | 19 | 22 | 18 | 24 | 13 | 21 | 25 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 4 | 3 | 5 | ||||||
| Accrued Liabilities Current | 0 | 1 | 1 | 2 | 3 | 2 | 3 | 2 | 1 | 1 | 3 | 5 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Long Term Debt Current | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Current | 0 | 1 | 1 | 2 | 2 | 2 | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 17 | 21 | 24 | 21 | 19 | 21 | 22 | 13 | 15 | 18 | 20 | 26 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Royalty Guarantees Commitments Amount | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | 0 | 0 | 1 | - | - | - | - | - | - | ||||||
| Liabilities | 23 | 27 | 30 | 28 | 26 | 28 | 28 | 20 | 21 | 24 | 26 | 27 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 194 | 193 | 192 | 190 | 171 | 171 | 170 | 169 | 168 | 167 | 167 | 164 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -195 | -192 | -189 | -187 | -184 | -180 | -175 | -170 | -165 | -178 | -171 | -166 | ||||||
| Stockholders Equity | -1 | 1 | 3 | 3 | -13 | -10 | -6 | -1 | 3 | -11 | -5 | -2 | ||||||
| Liabilities And Stockholders Equity | 22 | 28 | 32 | 31 | 13 | 19 | 22 | 18 | 24 | 13 | 21 | 25 | ||||||
| Series A Preferred Stock | 0 | 5 | - | - | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Liquidation Preference Value | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | ||||||
| Common Stock Shares Issued | 15 | 15 | 14 | 14 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 15 | 15 | 14 | 14 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDare Bioscience, Inc. (DARE) — SEC Financial Statements & Analysis
Dare Bioscience, Inc. (DARE) is a pharmaceutical preparations company, incorporated in DE. Dare Bioscience, Inc. trades on Nasdaq as: DARE. Dare Bioscience, Inc. (DARE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Dare Bioscience, Inc. carries a market cap of $31.42M, a P/E ratio of -2.86x, a P/B ratio of -56.09x, a P/S ratio of 23.44x, an enterprise value of $18.65M, and an EV/EBITDA multiple of -2.08x. On profitability, it posts an operating margin of -828.81%, a net margin of -819.62%, a Return on Equity (ROE) of 165.30%, and a Return on Assets (ROA) of -62.16%. Per share, it reports EPS of $-0.74, diluted EPS of $-0.74, free cash flow per share of $-0.79, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 17250.66% year-over-year, net income growth of -40.94% year-over-year, and EPS growth of -64.81% year-over-year. On the balance sheet, it maintains a current ratio of 0.99x, a quick ratio of 0.94x, working capital of $-236.46K, a debt-to-equity ratio of -40.94x, a debt ratio of 1.03, free cash flow of $-11.76M (TTM), and net debt of $-12.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $31.42M
- P/E TTM
- -2.86x
- EPS TTM
- $-0.74
- P/B TTM
- -56.09x
- ROE TTM
- 165.30%
- ROA TTM
- -62.16%
- Debt To Equity
- -40.94x
- Free Cash Flow TTM
- $-11.76M
- Net Revenue TTM Growth 1Y
- 17250.66%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Dare Bioscience, Inc. in?
Dare Bioscience, Inc. (DARE) operates in the Pharmaceutical Preparations industry.
What exchange does DARE trade on?
Dare Bioscience, Inc. (DARE) trades on the Nasdaq.
Where is Dare Bioscience, Inc. incorporated?
Dare Bioscience, Inc. is incorporated in DE.
When was Dare Bioscience, Inc. (DARE)'s most recent SEC filing?
Dare Bioscience, Inc. (DARE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is DARE's market cap?
Dare Bioscience, Inc. (DARE) has a market capitalization of $31.42M as of 2026-06-30.
What is DARE's EPS (earnings per share)?
Dare Bioscience, Inc. (DARE)'s trailing twelve month EPS is $-0.74 as of 2026-06-30.
What is DARE's ROE (return on equity)?
Dare Bioscience, Inc. (DARE)'s trailing twelve month Return on Equity (ROE) is 165.30% as of 2026-06-30.
What is DARE's ROA (return on assets)?
Dare Bioscience, Inc. (DARE)'s trailing twelve month Return on Assets (ROA) is -62.16% as of 2026-06-30.
What is DARE's EV/EBITDA?
Dare Bioscience, Inc. (DARE)'s trailing twelve month EV/EBITDA is -2.08x as of 2026-06-30.